LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

151.8 -2.4

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

151.57

Massimo

158.21

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

EPS

2.43

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+32.44% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

772M

8.7B

Apertura precedente

154.2

Chiusura precedente

151.8

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 mar 2026, 21:37 UTC

Acquisizioni, Fusioni, Takeovers

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Principali Notizie su Eventi

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Acquisizioni, Fusioni, Takeovers

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Discorsi di Mercato

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Discorsi di Mercato

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Acquisizioni, Fusioni, Takeovers

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Principali Notizie su Eventi

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Discorsi di Mercato

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Principali Notizie su Eventi

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Discorsi di Mercato

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Discorsi di Mercato

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Principali Notizie su Eventi

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Discorsi di Mercato

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Principali Notizie su Eventi

Trump Ends News Conference

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

32.44% in crescita

Previsioni per 12 mesi

Media 205.89 USD  32.44%

Alto 265 USD

Basso 175 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat